Skip to main content
Dr Layloma Rashid avatar
StocksAI

TECHi member

Dr Layloma Rashid

News Writer

@layloma

Followers

0

Following

0

Stories

309

258K total views

Author score

44

Connect

Dr Layloma Rashid brings a clinical lens to healthcare investing. She translates FDA filings, Phase 3 readouts, and PDUFA calendar dates into analysis readers can act on — covering large-cap pharma, medical-device makers, and the oncology and GLP-1 pipelines reshaping the sector. Her coverage weighs ClinicalTrials.gov data against management guidance and flags where sell-side models diverge from what trial design actually supports. She writes about drug development with the skepticism Phase 2 success rates deserve.

Sign in to followSign in to follow and get email alerts on new reports.

Track record

Quality & trust dashboard

Scores roll up from Dr Layloma Rashid's published work, reader engagement, fact-checks, and identity verification. All values 0-100.

Published

309

Articles on TECHi

Total views

258.5K

Across all work

Comments

0

Reader discussion

Saves

0

Bookmarked

Shares

0

Link-outs

Avg rating

Community

Author ScoreGetting started
44/100

TECHi's composite score — blends output volume, community ratings, fact-check accuracy, identity verification, and profile completeness.

TrustNo data yet

Average reader trust score across all published articles. Readers vote on whether claims feel sourced and balanced.

Fact-checkNo data yet

Average fact-check accuracy. Each article is reviewed by the community and editors against SEC filings, press releases, and primary sources.

EngagementNo data yet

Reader engagement: time on page, comments-per-view, share rate. High engagement signals the writing drove real discussion.

OutputExcellent
100/100

Publishing cadence and volume normalized over time. Rewards consistent output without overweighting prolific drive-bys.

QualityNo data yet

Editorial quality proxy from depth, citations, and original reporting markers — scored by editors during review.

IdentityNo data yet

Identity verification pending. Verified authors get a badge and higher trust weighting.

Profile completenessBuilding
57/100

Filled profile sections: headline, bio, avatar, social links, expertise, location. Higher = better reader context.

Publishing cadence

Output over 12 months

48 articles across 3 active months.

20
27
1
JunJulAugSepOctNovDecJanFebMarAprMay

Lead story

Most recent publish — open the full analysis or scroll for the full archive.

Archive

Latest analysis

Stocks, crypto, AI, and policy — reporting and commentary on TECHi (showing 48 of 309).

OpenAI Eyes NATO AI Contract After Pentagon Deal

OpenAI Eyes NATO AI Contract After Pentagon Deal

OpenAI is reportedly negotiating an AI contract with NATO's unclassified networks, backed by Microsoft and Amazon, following its Pentagon deal on February 27 — signaling a bold push into global defence AI amid rising geopolitical tensions.

Ali Sher
Infineon Technologies Eyes Humanoid Robot Chip Market

Infineon Technologies Eyes Humanoid Robot Chip Market

Infineon Technologies CEO Jochen Hanebeck sees strong growth potential in humanoid robot chips, leveraging autonomous driving expertise. Meanwhile, Norinchukin Bank posts its third consecutive quarterly profit but faces ongoing risks from unrealized bond losses and exposure to First Brands Group.

Dr Layloma Rashid

Topic mix

Coverage breakdown

Where Dr's recent stories cluster — jump into a desk.